Amgen Inc. (NASDAQ: AMGN ) declares $0.61/share quarterly dividend , in line with previous. Forward yield 1.99% Payable Sept. 5; for shareholders of record Aug. 14; ex-div Aug. 12. Post your comment!
HealthCare Pharmaceuticals ( OTCPK:BAYRY -2.4% ) ( OTCPK:BAYZF -1.7% ) and development partner Onyx Pharmaceuticals ( AMGN -0.3% ) report that the 537-patient Phase 3 clinical trial evaluating the safety and efficacy of Nexavar ( sorafenib
By Life Sciences Report : Aging baby boomers face increased cancer risk, and growing numbers of obese and overweight Americans face metabolic disorders that could lead to cardiovascular disease. Debjit Chattopadhyay of ROTH Capital Partners recommends that biotech investors consider these trends ...
License Application (BLA) for filgrastim filed by Novartis' ( NVS +0.3% ) Sandoz. The reference product is Amgen 's ( AMGN +0.1% ) Neupogen . Sandoz markets the product under the brand name Zarzio in more than 40 countries outside of
July 24 (Reuters) - U.S. regulators have accepted an application by Sandoz - the generics arm of Novartis - seeking approval for a copycat version of Amgen 's drug Neupogen, or filgrastim, for...
muscle and many other body tissues. ATRA's intellectual property was acquired from Amgen (NASDAQ: AMGN ). Pre-IPO VC firm Kleiner Perkins owns 18.6%. Amgen and Celgene (NASDAQ: CELG ) each own Complete Story »
By Abba's Aces: The last time I wrote about Amgen Inc. (NASDAQ: AMGN ) I stated, "Due to the low dividend payout ratio ..... 05% gain the S&P 500 (NYSEARCA: SPY ) posted. Amgen is a global biotech company (the first of its kind
Stoked by Friday's strong debut by Sage Therapeutics ( SAGE +1.7% ), more biotechs are slated to launch this week led by Amgen spin-off Atara Biotherapeutics , eye gel maker Ocular Therapeutix , biosimilar maker Pfenex and cancer immunotherapy firm
By DoctoRx : Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed. Biogen Idec (NASDAQ: BIIB ) fell more than 7% after that statement. Gilead Sciences (NASDAQ: GILD ) fell 5% peak-to-trough. Small ones got dumped big-time. Is it but a passing ...
leukemia, and the seriousness of the disease presents a dire need for a breakthrough drug to treat ALL. Recently, Amgen 's (NASDAQ: AMGN ) drug has been awarded the breakthrough status to treat adults with ALL. Prevalence of ALL Currently, there